MedTrace Logo

A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients

NCT00472264 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2009-07-02

No results posted yet for this study

Summary

It is hypothesised that there is a difference between the uptake of a radioactive substance (\[18F\]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

PROCEDURE

PET imaging

Medical imaging assessment

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00472264 on ClinicalTrials.gov